Outcomes of Systemic Janus Kinase Inhibitors Following Prior Dupilumab Use for Atopic Dermatitis: An Evidence-Based Review

Atopic dermatitis (AD) is a common, chronic, highly pruritic, inflammatory condition. Although several Janus kinase inhibitors (JAKi) have recently been approved for moderate-to-severe AD, limited guidance is available regarding the role of systemic JAKi in patients who have previously utilized dupilumab. We conducted a systematic review to evaluate JAKi outcomes for this specific population.